You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

Investigational Drug Information for Pevonedistat

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Pevonedistat?

Pevonedistat is an investigational drug.

There have been 34 clinical trials for Pevonedistat. The most recent clinical trial was a Phase 2 trial, which was initiated on August 13th 2019.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and Takeda.

There are one hundred and fourteen US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Pevonedistat
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic SyndromesTakedaPhase 2
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid TumorM.D. Anderson Cancer CenterPhase 1/Phase 2
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and PevonedistatMillennium Pharmaceuticals, Inc.Phase 2

See all Pevonedistat clinical trials

Clinical Trial Summary for Pevonedistat

Top disease conditions for Pevonedistat
Top clinical trial sponsors for Pevonedistat

See all Pevonedistat clinical trials

US Patents for Pevonedistat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pevonedistat ⤷  Sign Up Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA) ⤷  Sign Up
Pevonedistat ⤷  Sign Up Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Sign Up
Pevonedistat ⤷  Sign Up Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D- ]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate Millennium Pharmacetuicals, Inc. (Cambridge, MA) ⤷  Sign Up
Pevonedistat ⤷  Sign Up Peptidomimetic macrocycles as modulators of MCL-1 AILERON THERAPEUTICS, INC. (Cambridge, MA) ⤷  Sign Up
Pevonedistat ⤷  Sign Up Method of reducing titers of antibodies specific for a therapeutic agent Duke University (Durham, NC) ⤷  Sign Up
Pevonedistat ⤷  Sign Up Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL) ⤷  Sign Up
Pevonedistat ⤷  Sign Up Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases AbbVie Inc. (North Chicago, IL) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pevonedistat

Drugname Country Document Number Estimated Expiration Related US Patent
Pevonedistat European Patent Office EP3131552 2034-04-16 ⤷  Sign Up
Pevonedistat Spain ES2823756 2034-04-16 ⤷  Sign Up
Pevonedistat Japan JP2017514806 2034-04-16 ⤷  Sign Up
Pevonedistat Japan JP2019070012 2034-04-16 ⤷  Sign Up
Pevonedistat Japan JP2021059548 2034-04-16 ⤷  Sign Up
Pevonedistat Japan JP6838085 2034-04-16 ⤷  Sign Up
Pevonedistat New Zealand NZ629860 2034-04-16 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.